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Abstract
Xenobiotics can trigger degranulation of eosinophils and mast cells. In this process, the cells release several sub-
stances leading to bronchial hyperactivity, the main feature of atopic asthma (AA). GSTM1 and GSTT1 genes en-
code enzymes involved in the inactivation of these compounds. Both genes are polymorphic in humans and have a
null variant genotype in which both the gene and corresponding enzyme are absent. An increased risk for disease in
individualswiththenullGSTgenotypesistherefore,butthisissueiscontroversial.Theaimofthisstudywastoinves-
tigate the influence of the GSTM1 and GSTT1 genotypes on the occurrence of AA, as well as on its clinical manifes-
tations. Genomic DNA from 86 patients and 258 controls was analyzed by polymerase chain reaction. The frequency
of the GSTM1 null genotype in patients was higher than that found in controls (60.5% versus 40.3%, p = 0.002). In in-
dividuals with the GSTM1 null genotype the risk of manifested AA was 2.3-fold higher (95%CI: 1.4-3.7) than for oth-
ers. In contrast, similar frequencies of GSTT1 null and combined GSTM1 plus GSTT1 null genotypes were seen in
both groups. No differences in genotype frequencies were perceived in patients stratified by age, gender, ethnic ori-
gin, and severity of the disease. These results suggest that the inherited absence of the GSTM1 metabolic pathway
may alter the risk of AA in southeastern Brazilian children, although this must be confirmed by further studies with a
larger cohort of patients and age-matched controls from the distinct regions of the country.
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Atopic asthma (AA), a disease caused by a combina-
tion of genetic and environmental factors, is characterized
by a broad variety of clinical manifestations these ranging
fromincreasedbronchialsusceptibilityinhealthyindividu-
als to a lethal form.
Previous studies have shown that a great variety of
xenobiotics can trigger degranulation of eosinophils and
mast cells, with the subsequent release of various sub-
stances, active in bronchial inflammation and spasms, the
main events in pathogenesis of the disease (Demoly et al.,
1997). Enzymes of the glutathione S-transferase (GST)
system protect the bronchii from the effects of these agents
by transforming them into less active compounds (Demoly
et al., 1997; Scoggan et al., 1997; Hayes et al., 2005).
GSTM1 and GSTT1 genes of the GST system are polymor-
phic and homozygous null in about 40%-60% and
10%-20% of individuals of distinct ethnic origin (Hayes
and Pulford, 1995; Gattás et al., 2004; Hayes et al., 2005),
resultinginalackoftheactiveproteins.Apparently,people
with a reduced ability in detoxification or catabolism of
inductors of bronchial inflammation are under an increased
risk for AA (Ketley et al., 1975; Scoggan et al., 1997).
However, the association of GST null genotypes with this
risk is controversial (Ivaschenko et al., 2001; Freidin et al.,
2002; Brasch-Andersen et al., 2004; Saadat et al., 2004;
Tamer et al., 2004; Ercan et al., 2006; Holla et al., 2006;
Hanene et al., 2007; Mak et al., 2007; Salam et al., 2007;
Imbodenetal.,2008;Islametal.,2009;Castro-Gineretal.,
2009; Rogers et al., 2009).
The high prevalence of AA (Chatkin et al., 2003) and
environmentally-related diseases (Ruiz et al., 1994) in
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Short Communicationsoutheastern Brazil has already been described. Thus, the
identification of GST genotypes in AA patients and con-
trols from this part of the country was considered essential
for testing their influence in the risk and on clinical mani-
festations of the disease in the population as a whole.
Weanalyzed86consecutiveAApatients(medianage
10 years and range 7-17; 39 males and 47 females; 79 Cau-
casians and 7 Afro-Americans) seen at the University Hos-
pital of the State University of Campinas, from July, 2005
toJanuary,2006.Abackgroundhistoryofrecurrentandre-
versible symptoms of air passage obstruction, high serum
IgE levels, positive test results to at least one of the recog-
nised allergens inoculated in skin, and a family history of
allergy were required for AA diagnosis, in accordance with
current Global Initiative for Asthma (GINA) criteria
(GINA Report, Global Strategy for Asthma Management
and Prevention, 2009). None of the patients enrolled in this
study had any identifiable alcohol use or smoking history.
All the patients were students and were classified as having
a mild, moderate or severe form of AA, as previously de-
scribed by Warner et al. (1998). The control group con-
sisted of 258 healthy blood donors (median age 53 years
and range 25-62; 117 males and 141 females; 237 Cauca-
sians and 21 Afro-Americans) from the same University
Hospital, who were matched against the controls by gender
and ethnic origin, thereby providing a representative group
of the general population that seeks medical assistance in
this region. Both patients and controls were classified as
Caucasians or Afro-Americans based on individual pheno-
type. The study was approved by the local review board
guidelines, and all subjects gave written and informed con-
sent in accordance with the Helsinki Declaration.
Genomic DNA was obtained from the peripheral
bloodofallsubjects.GSTM1andGSTT1geneswereampli-
fied by multiplex polymerase chain reaction (PCR) in the
same reaction, including the amplification of a -globin
gene fragment used as a control of the DNA sample
(Arruda et al., 2001). Genotypes were analyzed by electro-
phoresisona2.0% agarosegel,andonlythosePCRsignals
were considered in which the corresponding -globin gene
internal control was evident.
Statistical significance of the differences between
groups was calculated by the chi-square or Fisher exact
tests. Crude odds ratios (ORs) were calculated and are
given with 95% confidence intervals (CI). Logistic regres-
sion analysis was used to obtain gender and ethnic ori-
gin-adjusted ORs. Factors with p < 0.05 were considered
statisticallysignificant.Allanalyseswereundertakenusing
the statistical package SAS System for Windows, version
8.1 (SAS Institute Incorporation, USA).
A high prevalence of the GSTM1 null genotype was
seen in our AA patients. Individuals with the GSTM1 null
genotype had a 2.3-fold increased risk for manifested dis-
ease than others. No differences in frequencies of the
GSTT1 null and GSTM1 plus GSTT1 null genotypes were
found in patients and controls. Individuals with distinct ge-
notypes incurred the same AA (Table 1). Similar frequen-
cies of the GSTM1 null, GSTT1 null and GSTM1 plus
GSTT1 null genotypes were seen in patients stratified by
age at diagnosis, gender, race, and severity of the disease
(Table 2).
Upon investigating the GSTM1 and GSTT1 genotype
frequencies of the GST system in Brazilian individuals, we
foundthattheGSTM1nullgenotypewasassociatedwithan
increased risk for AA. There are several explanations for
theroleofGSTsindiseasepathogenesis,thefirstbeingthat
xenobioticsarenotdischargedfromtheorganismintheab-
senceoftheseenzymes,andthereforemaytriggermastcell
degranulation (Demoly et al., 1997; Hayes et al., 2005).
Secondly, it is known that leukotrienes released by mast
cells and eosinophils, important compounds in bronchial
constriction, are inactivated by GSTs (Scoggan et al.,
1997). Thus, persistent bronchial spasms may be expected
in the absence of enzymes encoded by the GSTM1 and
GSTT1 genes. A further explanation is that GSTs are capa-
ble of binding steroid hormones, which are inhibitors of
eosinophils involved in a late stage of the allergic reaction,
and to transport them to tissues (Ketley et al., 1975). The
absence of these enzymes may, therefore, contribute to
asthma by abnormalities in the transport of inflammatory
inhibitors to bronchioles. Taken together, these observa-
tions suggest that GSTs act at different stages in the forma-
tion of an asthmatic reaction.
The results of 14 epidemiological studies on the role
of GST genotypes in asthma, undertaken in countries of the
northern hemisphere, were controversial. The GSTM1 null
genotype was associated with an increased risk for disease
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Table 1 - GSTM1 and GSTT1 genotypes in atopic asthma patients and controls.
GSTM1 GSTT1 GSTM1/T1
Present n (%) Null n (%) Present n (%) Null n (%) Both present n (%) One null n (%) Both null n (%)
Patients 34 (39.5) 52 (60.5) 72 (83.7) 14 (16.3) 27 (31.4) 52 (60.5) 7 (8.1)
Controls 154 (59.7) 104 (40.3) 213 (82.6) 45 (17.4) 130 (50.4) 107 (41.5) 21 (8.1)
OR (CI 95%) 1.0 (ref) 2.3 (1.3-3.3) 1.0 (ref) 0.9 (0.5-1.7) 1.0 (ref) 2.3 (1.4-4.0) 1.6 (0.6-4.1)
p value 0.002 0.870 0.002 0.425
OR: odds ratio; CI: confidence interval.in some reports (Ivaschenko et al., 2001; Brasch-Andersen
et al., 2004; Saadat et al., 2004; Tamer et al., 2004; Hanene
et al., 2007; Islam et al., 2009; Rogers et al., 2009), but not
in others (Freidin et al., 2002; Ercan et al., 2006; Holla et
al., 2006; Mak et al., 2007; Salam et al., 2007; Imboden et
al., 2008; Castro-Giner et al., 2009). Similarly, an in-
creased risk was seen in individuals with the GSTT1 null
genotype in some studies (Ivaschenko et al., 2001;
Brasch-Andersen et al., 2004; Saadat et al., 2004; Tamer et
al., 2004; Hanene et al., 2007), whereas no association of
the disease with this genotype was noted by others (Freidin
et al., 2002; Ercan et al., 2006; Holla et al., 2006; Mak et
al., 2007; Salam et al., 2007; Imboden et al., 2008; Islam et
al., 2009; Castro-Giner et al., 2009; Rogers et al., 2009).
Differences in gene frequencies among various ethnic
groups, as well as exposure to environmental chemical
agents in the various countries, may explain the differences
encountered. The ethnic origin of the Brazilian population
is highly heterogeneous (Gattás et al., 2004), consisting of
indigenous Amerindians and immigrants from Europe, Af-
ricaandAsiawhilstpopulationsinthenorthernhemisphere
are usually characterised by ethnical homogeneity. In fact,
the frequencies of GSTM1 and GSTT1 null genotypes in
controlsvariedfrom40.8%(Turkey)to73.5%(Russia)and
22.1% (Czech Republic) to 53.3% (China), respectively,
among individuals of distinct populations in consistent
studies (Hayes et al., 2005). On the other hand, Brazilian
workers are frequently exposed to numerous chemical
agents, such as, hexachlorobenzene, carbon tetrachloride,
perchloroethylene, solvents, benzopyrene, alachlor,
atrazine, lindane and methyl parathion, some of which are
known to be metabolised by the enzymes of the GST sys-
tem (Hayes et al., 2005), besides being involved in bron-
chial reactivity (Demoly et al., 1997). Unfortunately there
was a lack of reliable data focusing individual chemical ex-
posure on the part of our patients and controls, as well as
those enrolled in other studies. All the enrolled AA patients
were childrens, and therefore apparently had no history of
excessive exposure to chemical agents. However, we can
not exclude chemical and tobacco exposition in our con-
trols, who were older than our patients.
We also analyzed GST genotypes in clinical features
of AA patients, and found no role for GSTM1 and GST1 by
age at diagnosis, gender, ethnic origin and severity of the
disease. Freidin et al. (2002) and Ercan et al. (2006) also
found no association of GST genotypes with severity of the
disease. On the contrary, Carrol et al. (2005) and Holla et
al. (2006) found an excess of GSTM1 null genotype in pa-
tients with malfunction of the lung, thereby implying that a
lack of the M1 enzyme could contribute to lung damage in
patients with the disease.
In summary, our results are suggestive that the inher-
ited absence of the GSTM1 metabolic pathway may alter
theriskformanifestedAAinourregion,eventhoughnoin-
fluence on the severity of the disease was detected. How-
ever, these results must be confirmed by further studies
with a larger cohort of patients and age-matched controls
from distinct regions of the country.
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Table 2 - GSTM1 and T1 genotypes in atopic asthma patients stratified by pertinent characteristics.
Clinical features n GSTM1 GSTT1 GSTM1/T1
Present
n (%)
Null
n (%)
Present
n (%)
Null
n (%)
Both present
n (%)
One null
n (%)
Both null
n (%)
Median age at diagnosis 86
 10 years 51 23 (26.8) 28 (32.5) 42 (48.8) 9 (10.5) 19 (22.1) 27 (31.4) 5 (5.8)
> 10 years 35 11 (12.8) 24 (27.9) 30 (34.9) 5 (5.8) 8 (9.3) 25 (29.1) 2 (2.3)
p value 0.30 0.90 reference 0.18 0.96
Gender 86
Male 39 16 (18.7) 23 (26.7) 35 (40.7) 4 (4.7) 13 (15.2) 25 (29.0) 1 (1.2)
Female 47 18 (20.9) 29 (33.7) 37 (43.0) 10 (11.6) 14 (16.2) 27 (31.4) 6 (7.0)
p value 0.97 0.28 reference 0.99 0.23
Ethnic origin 86
Caucasian 79 30 (34.9) 49 (56.9) 66 (76.7) 13 (15.1) 23 (26.8) 50 (58.0) 6 (7.0)
Afro-American 7 4 (4.7) 3 (3.5) 6 (7.0) 1 (1.2) 4 (4.7) 2 (2.3) 1 (1.2)
p value 0.55 0.88 reference 0.19 0.97
Severity of disease 86
Mild 28 13 (15.2) 15 (17.4) 22 (25.6) 6 (7.0) 9 (10.5) 17 (19.7) 2 (2.3)
Moderate 21 6 (7.0) 15 (17.4) 19 (22.1) 2 (2.3) 6 (7.0) 13 (15.2) 2 (2.3)
Severe 37 15 (17.4) 22 (25.6) 31 (36.0) 6 (7.0) 12 (13.9) 22 (25.6) 3 (3.5)
p value 0.44 0.53 reference 0.96 0.93References
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